SCHEMBL1005769

SCHEMBL1005769

COC(=O)c1cc2c([nH]1)CCCC2=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CYP1A2 P05177 1/20 0.46
PKN1 Q16512 1/20 0.42
PKN2 Q16513 1/20 0.42
KDM4E B2RXH2 3/20 0.41
GAA P10253 3/20 0.41
GLA P06280 2/20 0.41
USP2 O75604 1/20 0.39
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 2/20 0.37
HTT P42858 2/20 0.37
MEN1 O00255 1/20 0.37
FGB P02675 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1004484 0.90 CYP1A2 (0.49) TSHRL3MBTL1CYP1A2KDM4EGAA
SCHEMBL2077218 0.84 BRD4 (0.47) L3MBTL1KDM4EGAAGLAMAPT
SCHEMBL18248776 0.83 TSHR (0.48) TSHRL3MBTL1PKN1PKN2KDM4E
SCHEMBL10264129 0.80 ALDH1A1 (0.49) TSHRL3MBTL1CYP1A2PKN1PKN2
SCHEMBL21975324 0.78 HRH4 (0.54) TSHRL3MBTL1CYP1A2KDM4EGAA
SCHEMBL15101736 0.78 HRH4 (0.54) TSHRL3MBTL1CYP1A2KDM4EGAA
SCHEMBL10263410 0.76 PKN1 (0.43) TSHRL3MBTL1PKN1PKN2KDM4E
SCHEMBL1004062 0.76 CYP1A2 (0.44) CYP1A2KDM4EGAAGLAMAPT
SCHEMBL7047669 0.76 HRH4 (0.55) TSHRL3MBTL1CYP1A2KDM4EGAA
SCHEMBL1005211 0.75 CYP1A2 (0.42) L3MBTL1CYP1A2KDM4EGAAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360149-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2024-10-31 US disclosed
US-12054494-B2 Compound with anticancer activity KYOWA KIRIN CO., LTD. (JP) 2024-08-06 US disclosed
EP-3778573-B1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO LTD (JP) 2024-04-24 EP disclosed
CN-111936468-B Compounds with anticancer activity 协和麒麟株式会社 2024-03-08 CN disclosed
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2023-05-25 US disclosed
US-11629152-B2 Compound with anticancer activity KYOWA KIRIN CO., LTD. (JP) 2023-04-18 US disclosed
US-11591344-B2 2023-02-28 US disclosed
US-20220378923-A1 BET DEGRADER KYOWA KIRIN CO., LTD. (JP) 2022-12-01 US disclosed
EP-4039333-A1 BET DEGRADER Kyowa Kirin Co., Ltd. (JP) 2022-08-10 EP disclosed
CN-114502534-A BET degradant 协和麒麟株式会社 2022-05-13 CN disclosed
US-7615572-B2 4,5-substituted pyrazole-3-carboxylic acids/esters/salts; D-amino acid oxidase (DAAO) inhibitors; increase D-Serine level; reduce level of toxic products of D-Serine oxidation; activate N-methyl-D-aspartate NMDA-glutamate receptors; neuropathic agent, schizophrenia, Alzheimer's, anaxia SEPRACOR INC. (US) 2009-11-10 US disclosed
US-20090170916-A1 Pyrrole and Pyrazole DAAO Inhibitors SEPRACOR INC. (US) 2009-07-02 US disclosed
US-20090170916-A1 Pyrrole and Pyrazole DAAO Inhibitors SEPRACOR INC. (US) 2009-07-02 US disclosed
EP-2074092-A2 INHIBITORS OF D-AMINO ACID OXIDASE Sepracor Inc. (US) 2009-07-01 EP disclosed
US-20090099248-A1 INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2009-04-16 US disclosed
US-7488747-B2 Pyrrole and pyrazole DAAO inhibitors SEPRACOR INC. (US) 2009-02-10 US disclosed
US-7488747-B2 Pyrrole and pyrazole DAAO inhibitors SEPRACOR INC. (US) 2009-02-10 US disclosed
WO-2008089453-A2 INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2008-07-24 WO disclosed
WO-2005066135-A2 PYRROLE AND PYRAZOLE DAAO INHIBITORS SEPRACOR INC. (US) 2005-07-21 WO disclosed
US-20050143443-A1 Pyrrole and pyrazole DAAO inhibitors SEPRACOR INC. (US) 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143443-A1 Pyrrole and pyrazole DAAO inhibitors DDO, DAO, SRR TSHR 1282/4885L3MBTL1 398/4885CYP1A2 3265/4885
US-12054494-B2 Compound with anticancer activity TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 TSHR 4169/4885L3MBTL1 631/4885CYP1A2 2527/4885
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 TSHR 4169/4885L3MBTL1 631/4885CYP1A2 2527/4885
US-11591344-B2 H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2, TP53 TSHR 3328/4885L3MBTL1 1054/4885CYP1A2 1423/4885
US-20090099248-A1 INHIBITORS OF D-AMINO ACID OXIDASE DDO, DAO, ACHE TSHR 4620/4885L3MBTL1 962/4885CYP1A2 2041/4885
US-20220378923-A1 BET DEGRADER BET1, BRD4, BICRA TSHR 1310/4885L3MBTL1 1929/4885CYP1A2 2686/4885
US-11629152-B2 Compound with anticancer activity TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 TSHR 4169/4885L3MBTL1 631/4885CYP1A2 2527/4885
US-20090170916-A1 Pyrrole and Pyrazole DAAO Inhibitors DDO, DAO, SRR TSHR 1282/4885L3MBTL1 398/4885CYP1A2 3265/4885
US-20240360149-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 TSHR 4169/4885L3MBTL1 631/4885CYP1A2 2527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.